Cost-effectiveness Analysis of Gene-based Therapies for Patients with Spinal Muscular Atrophy Type I in Australia

Overview

Journal J Neurol

Specialty Neurology

Date 2022 Aug 18

PMID 35980467

Authors

Tianjiao Wang

Paul Scuffham

Joshua Byrnes

Martin Downes

Affiliations

Soon will be listed here.

Abstract

Introduction: Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder and regarded as one of the most frequent genetic causes of infant mortality. The aim of this study is to develop a cost-effectiveness analysis of AVXS-101 (Onasemnogene Abeparvovec/Zolgensma) and nusinersen (Spinraza) for SMA to inform decision-making on reimbursement policies in Australia.

Methods: A Markov model was developed with five health states to evaluate the costs and effects for patients with SMA Type I from a healthcare system perspective over a time-horizon of 100 years. The model parameters were based on clinical trials, parametric distributions, published literature, and Australian registries. One-way and probabilistic sensitivity analysis were performed to appraise the uncertainties of the parameters in the model. A threshold analysis was conducted to estimate the cost of AVXS-101 of being cost-effective.

Results: The incremental cost-effectiveness ratio (ICER) of AVXS-101 was $1,808,471 per quality-adjusted life year (QALY) and that of nusinersen was $2,772,798 per QALY, compared to standard of care, respectively. The ICER of AVXS-101 was $1,238,288 per QALY compared to nusinersen. The key drivers influencing on ICERs were costs of using treatments and utility values of sitting and walking independently.

Conclusion: Both nusinersen and AVXS-101 resulted in health benefits, but they were not cost-effective with a commonly used willingness-to-pay (WTP) threshold of $50,000 per QALY. Developing high-quality clinical data and exploring appropriate WTP thresholds are critical for decision-making on reimbursement policies in the treatment of rare diseases.

Citing Articles

The Socio-Economic Burden of Spinal Muscular Atrophy: A Cost-of-Illness Study in Bulgaria.

Dzhambazova E, Kostadinov K, Tsenkova-Toncheva L, Galabova F, Ezeldin F, Iskrov G Healthcare (Basel). 2025; 13(4).

PMID: 39997276 PMC: 11855038. DOI: 10.3390/healthcare13040401.

Antisense oligonucleotides and their applications in rare neurological diseases.

McDowall S, Aung-Htut M, Wilton S, Li D Front Neurosci. 2024; 18:1414658.

PMID: 39376536 PMC: 11456401. DOI: 10.3389/fnins.2024.1414658.

Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis.

Khuntha S, Prawjaeng J, Ponragdee K, Sanmaneechai O, Srinonprasert V, Leelahavarong P Appl Health Econ Health Policy. 2024; 23(2):277-290.

PMID: 39333302 PMC: 11811457. DOI: 10.1007/s40258-024-00915-y.

Multiplex Real-Time PCR-Based Newborn Screening for Severe Primary Immunodeficiency and Spinal Muscular Atrophy in Osaka, Japan: Our Results after 3 Years.

Kimizu T, Nozaki M, Okada Y, Sawada A, Morisaki M, Fujita H Genes (Basel). 2024; 15(3).

PMID: 38540372 PMC: 10970021. DOI: 10.3390/genes15030314.

Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England.

Weidlich D, Servais L, Kausar I, Howells R, Bischof M Neurol Ther. 2023; 12(4):1205-1220.

PMID: 37222861 PMC: 10310612. DOI: 10.1007/s40120-023-00489-2.

References

Oskoui M, Levy G, Garland C, Gray J, OHagen J, De Vivo D . The changing natural history of spinal muscular atrophy type 1. Neurology. 2007; 69(20):1931-6. DOI: 10.1212/01.wnl.0000290830.40544.b9. View

Verhaart I, Robertson A, Wilson I, Aartsma-Rus A, Cameron S, Jones C . Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017; 12(1):124. PMC: 5496354. DOI: 10.1186/s13023-017-0671-8. View

Guyot P, Ades A, Ouwens M, Welton N . Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12:9. PMC: 3313891. DOI: 10.1186/1471-2288-12-9. View

Mendell J, Al-Zaidy S, Shell R, Arnold W, Rodino-Klapac L, Prior T . Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017; 377(18):1713-1722. DOI: 10.1056/NEJMoa1706198. View

McCabe C, Claxton K, Tsuchiya A . Orphan drugs and the NHS: should we value rarity?. BMJ. 2005; 331(7523):1016-9. PMC: 1273462. DOI: 10.1136/bmj.331.7523.1016. View

Zuluaga-Sanchez S, Teynor M, Knight C, Thompson R, Lundqvist T, Ekelund M . Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden. Pharmacoeconomics. 2019; 37(6):845-865. DOI: 10.1007/s40273-019-00769-6. View

Jalali A, Rothwell E, Botkin J, Anderson R, Butterfield R, Nelson R . Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy. J Pediatr. 2020; 227:274-280.e2. PMC: 7686158. DOI: 10.1016/j.jpeds.2020.07.033. View

Woods B, Revill P, Sculpher M, Claxton K . Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value Health. 2016; 19(8):929-935. PMC: 5193154. DOI: 10.1016/j.jval.2016.02.017. View

Broekhoff T, Sweegers C, Krijkamp E, Mantel-Teeuwisse A, Leufkens H, Goettsch W . Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios. Value Health. 2021; 24(6):759-769. DOI: 10.1016/j.jval.2020.09.021. View

10.

Sugarman E, Nagan N, Zhu H, Akmaev V, Zhou Z, Rohlfs E . Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2011; 20(1):27-32. PMC: 3234503. DOI: 10.1038/ejhg.2011.134. View

11.

de Sanctis R, Coratti G, Pasternak A, Montes J, Pane M, Mazzone E . Developmental milestones in type I spinal muscular atrophy. Neuromuscul Disord. 2016; 26(11):754-759. PMC: 5091285. DOI: 10.1016/j.nmd.2016.10.002. View

12.

Archibald A, Smith M, Burgess T, Scarff K, Elliott J, Hunt C . Reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy in Australia: outcomes of 12,000 tests. Genet Med. 2017; 20(5):513-523. DOI: 10.1038/gim.2017.134. View

13.

Mercuri E, Finkel R, Muntoni F, Wirth B, Montes J, Main M . Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018; 28(2):103-115. DOI: 10.1016/j.nmd.2017.11.005. View

14.

Chung B, Wong V, Ip P . Spinal muscular atrophy: survival pattern and functional status. Pediatrics. 2004; 114(5):e548-53. DOI: 10.1542/peds.2004-0668. View

15.

Zerres K, Rudnik-Schoneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I . A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997; 146(1):67-72. DOI: 10.1016/s0022-510x(96)00284-5. View

16.

Lunn M, Wang C . Spinal muscular atrophy. Lancet. 2008; 371(9630):2120-33. DOI: 10.1016/S0140-6736(08)60921-6. View

17.

Diaby V, Adunlin G, Montero A . Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2013; 32(2):101-8. DOI: 10.1007/s40273-013-0123-9. View

18.

Wurster C, Ludolph A . Nusinersen for spinal muscular atrophy. Ther Adv Neurol Disord. 2018; 11:1756285618754459. PMC: 5858681. DOI: 10.1177/1756285618754459. View

19.

Attema A, Brouwer W, Claxton K . Discounting in Economic Evaluations. Pharmacoeconomics. 2018; 36(7):745-758. PMC: 5999124. DOI: 10.1007/s40273-018-0672-z. View

20.

Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M . Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021; 16(1):47. PMC: 7824917. DOI: 10.1186/s13023-021-01695-7. View